Tecovirimat is safe but ineffective as treatment for clade II mpox
The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...
Technology Networks10h
Tecovirimat Is Safe but Ineffective as a Treatment for Mpox
The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...
ACTG Presents Data from Mpox Study STOMP at CROI
ACTG, a global clinical trials network focused on HIV and other infectious diseases, recently presented data demonstrating ...
NIH Trial Finds Tecovirimat Ineffective As Monotherapy For Mpox
A NIH-led trial found tecovirimat ineffective in reducing mpox lesion healing time or pain relief. The study was halted in 2024, with findings presented at CROI 2025.
Mirage News18h
Tecovirimat Safe But Ineffective for Clade II Mpox
The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...
NIH: Siga’s tecovirimat safe, but ineffective as treatment for Clade II Mpox
The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve ...
SIGA Technologies, Inc. (NASDAQ:SIGA) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript March 11, 2025 Operator: Welcome to the SIGA Business Update Call. Before we turn the call ...
Le Lézard18h
Rivus Pharmaceuticals Announces Publication of Phase 2a HuMAIN Trial of HU6 in Patients with Obesity-Related Heart Failure in JAMA Cardiology
Treatment with HU6 led to significant reductions in body fat and abdominal visceral fat while preserving skeletal muscle in patients with obesity-related heart failure with preserved ejection fraction ...
Le Lézard18h
Urolithin A Market Grows Strongly with Rising Demand for Anti-Aging and Health Supplements | Valuates Reports
Urolithin A Market is Segmented by Type (Purity: >98%, Purity: >99%), by Application (Food Additives, Cosmetics, Drugs and ...